Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131-I mIBG, Nivolumab, and Dinutuximab Beta in Relapsed/Refractory Neuroblastoma
NCT02914405Phase 1Active, not recruiting
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- May 2018
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of nivolumab and Dinutuximab beta in neuroblastoma (3 cohorts), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 2 years. Started May 2018; status: active, not recruiting.
02
Drugs
nivolumabDinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02914405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914405.